These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. [Drug therapy in Parkinson's disease]. van Hilten JJ; Roos RA Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151 [TBL] [Abstract][Full Text] [Related]
15. Should levodopa be used anymore? Zegers de Beyl D Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242 [TBL] [Abstract][Full Text] [Related]
16. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia. Stacy M; Galbreath A Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491 [TBL] [Abstract][Full Text] [Related]
17. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. Stocchi F J Neurol; 2011 May; 258(Suppl 2):S316-22. PubMed ID: 21560062 [TBL] [Abstract][Full Text] [Related]
18. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
19. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease. Linazasoro G; J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015 [TBL] [Abstract][Full Text] [Related]
20. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease]. Klivényi P; Vécsei L Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]